Dr Vladimir ZelenkoDr Brian TysonDr Harvey RischDr Didier Raoult In progress
Read MoreMonth: October 2021
Dr Brian Tyson
Brian Tyson is a board certified family physician in El Centro, California. California physician Brian Tyson successfully treated thousands of patients with hydroxychloroquine in his clinic. In the studio of One America News , he said he has now cured nearly 5,000 patients. Two patients died and six had to go to hospital. The doctor also warned that an experimental vaccine puts people at risk unnecessarily. When asked how this personal HCQ involvement began for him, Dr Tyson tells a tragic story of how his daughter’s music manager went to…
Read MoreDr Harvey Risch
Dr Harvey Risch: “US cumulative deaths through July 15 are 140,000. Had we permitted HCQ use liberally, we would have saved half, 70,000 and it is very possible we could have saved 3/4, 105,000.” Interview with Dr Simone Gold, July 15, 2020
Read MoreDr. Vladimir Zelenko
(Sadly, Dr Zelenko passed away in June 2022 after a long fight with cancer. An obituary is here) Interviewed on the Highwire by Del Bigtree 3 July 2020 {https://thehighwire.com/} Dr. Zelenko comes on about 42 mins in. (Prior interviewees: John Ziegler, Senior columnist; Reinette Senum, Mayor Nevada City, CA) Approximate transcript (may be incomplete at the beginning) Referring to Didier Raoult’s work and others…they were doing it in the lab or patients in the hospital. My patients were outpatients. The best solution to the respiratory crisis is to prevent people…
Read MoreDoctors’ statements
Country-level comparisons
In the early part of the pandemic, many people charted the emerging picture of high Covid-19 death rates in developed countries with a large pharmaceutical industry presence (whose governments generally opposed HCQ) and low rates in poorer countries (that already used HCQ or were quick to adopt it). This resulted in a number of comparative analyses. Summary (i) An analysis by the group Americas Frontline Doctors by country, showed that access to HCQ was strongly linked to lower Covid-19 mortality. (ii) A worldwide country comparison generated automatically by the website…
Read More14 statistically significant
Lead author Improvement RR [CI] Outcome Treatment Control Dose (4d) Gautret 66% 0.34 [0.17-0.68] viral+ 6/20 14/16 2.4g Esper 64% 0.36 [0.15-0.87] hosp. 8/412 12/224 2.0 Huang (ES) 59% 0.41 [0.26-0.66] viral time 32/32 37/37 2.0g (c) Chen (RCT) 72% 0.28 [0.10-0.82] viral time 18/18 12/12 1.6g Hong 65% 0.35 [0.13-0.72] viral+ 42/42 48/48 n/a Bernabeu-Wittel 59% 0.41 [0.36-0.95] death 189 (n) 83 (n) 2.0g Ly 56% 0.44 [0.26-0.75] death 18/116 29/110 2.4g Heras 96% 0.04 [0.02-0.09] death 8/70 16/30 n/a Sulaiman 64% 0.36 [0.17-0.80] death 7/1,817 54/3,724 2.0g Szente Fonseca …
Read MoreAccinelli – completing the picture
As noted, 30+ other studies strongly indicate the merits of treating Covid-19 early with Hydroxychloroquine. One notable study not on the list provides quantification and important wider context. Accinelli et al, Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate https://www.sciencedirect.com/science/article/pii/S1477893921002040 Summary of importance The Accinelli study has relevance as yet another basic hydroxychloroquine Covid-19 early treatment study. So why is it not on the list? It’s because everyone in the study received HCQ. It has much wider relevance because it studied the effect…
Read MoreSome Main Studies
Virtually all of the 31/32 studies of early treatment using hydroxychlorquine had positive primary outcomes. In a sign test, if in reality HCQ had no benefit, the odds this happening is billions to one against. 14 of the outcomes were statistically significant. Here are some of those studies, borrowing from the useful descriptions of c19study.com: Sulaiman et al. “This observational prospective cohort study took place in 238 ambulatory fever clinics in Saudi Arabia, which followed the Ministry of Health (MOH) COVID-19 treatment guideline. This guideline included multiple treatment options for…
Read More